Eversept Partners’s Myriad Genetics MYGN Stock Holding History

Eversept Partners’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-181,961	Closed	-$4.45M	–	76
2024 Q2	$4.45M	Buy	+181,961	New	+$3.99M	0.3%	47

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Eversept Partners's MYGN Position: Q3 2024 in Review

Eversept Partners sold out of Myriad Genetics (MYGN) in Q3 2024, closing a stake of 181,961 shares — an estimated $4.45M sold.

Eversept Partners first reported a position in MYGN in Q2 2024 and held it in 1 quarter. The position peaked at $4.45M in Q2 2024. 246 funds tracked by Wall St. Rank hold MYGN as of Q3 2024.

Eversept Partners reported no remaining Myriad Genetics position as of Q3 2024 after selling out during the quarter.
Eversept Partners sold 181,961 Myriad Genetics shares in Q3 2024, an estimated $4.45M.
Eversept Partners first reported a position in Myriad Genetics in Q2 2024 and held it in 1 quarter.
Eversept Partners's Myriad Genetics position peaked at $4.45M in Q2 2024.
246 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2024.

Based on Eversept Partners's 13F filing for Q3 2024, filed 14 Nov 2024.